Baird raises Labcorp Holdings target to $338
Baird analyst Eric Coldwell maintained an Outperform rating on Labcorp Holdings, raising the price target to $338 from $335. Separately, B of A Securities analyst Michael Ryskin maintained a Buy rating with a price target of $320, up from $300.
*this image is generated using AI for illustrative purposes only.
Baird analyst Eric Coldwell has maintained an Outperform rating on Labcorp Holdings while raising the price target to $338 from $335. This adjustment signals increased confidence in the company's performance potential. Separately, B of A Securities analyst Michael Ryskin has maintained a Buy rating on the stock with a price target of $320, up from $300.
Rating and Target Details
The revised price target of $338 from Baird represents an increase from the previous target of $335. The Outperform rating remains unchanged, indicating a continued positive outlook on the stock.
| Firm | Analyst | Rating | Previous Target | New Target |
|---|---|---|---|---|
| Baird | Eric Coldwell | Outperform | $335 | $338 |
| B of A Securities | Michael Ryskin | Buy | $300 | $320 |
Labcorp Holdings trades on the NYSE under the ticker symbol LH.
What specific operational or financial metrics are driving the increased confidence from Baird and B of A Securities?
How might Labcorp's recent performance compare to its competitors in the diagnostic services sector?
What potential market or regulatory changes could impact Labcorp's ability to meet these revised price targets?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
